PubMed:33152450
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 853-856 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
| T2 | 1068-1071 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 64-72 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T2 | 190-214 | Disease | denotes | Coronavirus disease-2019 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T3 | 216-224 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T4 | 270-278 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T5 | 474-521 | Disease | denotes | severe acute respiratory syndrome-coronavirus-2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T6 | 474-507 | Disease | denotes | severe acute respiratory syndrome | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T7 | 523-531 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T8 | 588-596 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T9 | 1447-1455 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T10 | 1488-1496 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 82-87 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
| T2 | 360-362 | http://purl.obolibrary.org/obo/CLO_0001547 | denotes | AP |
| T3 | 396-400 | http://purl.obolibrary.org/obo/CLO_0007919 | denotes | n=18 |
| T4 | 396-400 | http://purl.obolibrary.org/obo/CLO_0007920 | denotes | n=18 |
| T5 | 677-680 | http://purl.obolibrary.org/obo/CLO_0050884 | denotes | ten |
| T6 | 947-949 | http://purl.obolibrary.org/obo/CLO_0001547 | denotes | AP |
| T7 | 1164-1166 | http://purl.obolibrary.org/obo/CLO_0001547 | denotes | AP |
| T8 | 1272-1275 | http://purl.obolibrary.org/obo/CLO_0050884 | denotes | ten |
| T9 | 1532-1534 | http://purl.obolibrary.org/obo/CLO_0001547 | denotes | AP |
| T10 | 1646-1648 | http://purl.obolibrary.org/obo/CLO_0001547 | denotes | AP |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 82-87 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T2 | 335-346 | Chemical | denotes | artemisinin | http://purl.obolibrary.org/obo/CHEBI_223316 |
| T3 | 347-358 | Chemical | denotes | piperaquine | http://purl.obolibrary.org/obo/CHEBI_91231 |
| T4 | 360-362 | Chemical | denotes | AP | http://purl.obolibrary.org/obo/CHEBI_28971|http://purl.obolibrary.org/obo/CHEBI_73393|http://purl.obolibrary.org/obo/CHEBI_81686 |
| T7 | 364-369 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T8 | 389-394 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T9 | 947-949 | Chemical | denotes | AP | http://purl.obolibrary.org/obo/CHEBI_28971|http://purl.obolibrary.org/obo/CHEBI_73393|http://purl.obolibrary.org/obo/CHEBI_81686 |
| T12 | 950-955 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T13 | 1010-1015 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T14 | 1164-1166 | Chemical | denotes | AP | http://purl.obolibrary.org/obo/CHEBI_28971|http://purl.obolibrary.org/obo/CHEBI_73393|http://purl.obolibrary.org/obo/CHEBI_81686 |
| T17 | 1167-1172 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T18 | 1243-1248 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T19 | 1532-1534 | Chemical | denotes | AP | http://purl.obolibrary.org/obo/CHEBI_28971|http://purl.obolibrary.org/obo/CHEBI_73393|http://purl.obolibrary.org/obo/CHEBI_81686 |
| T22 | 1535-1540 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T23 | 1566-1571 | Chemical | denotes | group | http://purl.obolibrary.org/obo/CHEBI_24433 |
| T24 | 1646-1648 | Chemical | denotes | AP | http://purl.obolibrary.org/obo/CHEBI_28971|http://purl.obolibrary.org/obo/CHEBI_73393|http://purl.obolibrary.org/obo/CHEBI_81686 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2 | 23-46 | Chemical | denotes | Artemisinin-Piperaquine | |
| 3 | 64-72 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 18 | 176-184 | Species | denotes | patients | Tax:9606 |
| 19 | 190-214 | Disease | denotes | Coronavirus disease-2019 | MESH:C000657245 |
| 20 | 216-224 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 21 | 246-254 | Species | denotes | patients | Tax:9606 |
| 22 | 270-278 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 23 | 335-358 | Chemical | denotes | artemisinin-piperaquine | |
| 24 | 474-521 | Species | denotes | severe acute respiratory syndrome-coronavirus-2 | Tax:2697049 |
| 25 | 523-533 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 26 | 557-569 | Species | denotes | participants | Tax:9606 |
| 27 | 588-598 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 28 | 1035-1043 | Species | denotes | patients | Tax:9606 |
| 29 | 1416-1424 | Species | denotes | patients | Tax:9606 |
| 30 | 1447-1455 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 31 | 1488-1498 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-126 | Sentence | denotes | Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial. |
| T2 | 127-138 | Sentence | denotes | BACKGROUND: |
| T3 | 139-226 | Sentence | denotes | There are no effective therapies for patients with Coronavirus disease-2019 (COVID-19). |
| T4 | 227-235 | Sentence | denotes | METHODS: |
| T5 | 236-402 | Sentence | denotes | Forty-one patients with confirmed COVID-19 were enrolled in the study and divided into two groups: artemisinin-piperaquine (AP) group (n=23) and control group (n=18). |
| T6 | 403-624 | Sentence | denotes | The primary outcome was the time taken to reach undetectable levels of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and the percentage of participants with undetectable SARS-CoV-2 on day 7, 10, 14, and 28. |
| T7 | 625-801 | Sentence | denotes | The computed tomography (CT) imaging changes within ten days, the corrected QT interval changes, adverse events, and abnormal laboratory parameters were the secondary outcomes. |
| T8 | 802-810 | Sentence | denotes | RESULTS: |
| T9 | 811-932 | Sentence | denotes | The mean time to reach undetectable viral RNA (mean± standard deviation) was 10.6±1.1 days (95% confidence interval [CI]: |
| T10 | 933-982 | Sentence | denotes | 8.4-12.8) for AP group and 19.3±2.1 days (95% CI: |
| T11 | 983-1016 | Sentence | denotes | 15.1-23.5) for the control group. |
| T12 | 1017-1249 | Sentence | denotes | The percentage of patients with undetectable viral RNA on day 7, 10, 14, 21, and 28 were 26.1%, 43.5%, 78.3%, 100%, and 100%, respectively, in the AP group and 5.6%, 16.7%, 44.4%, 55.6% and 72.2%, respectively, in the control group. |
| T13 | 1250-1362 | Sentence | denotes | The CT imaging within ten days post-treatment showed no significant differences between the two groups (p>0.05). |
| T14 | 1363-1399 | Sentence | denotes | Both groups had mild adverse events. |
| T15 | 1400-1412 | Sentence | denotes | CONCLUSIONS: |
| T16 | 1413-1572 | Sentence | denotes | In patients with mild to moderate COVID-19, the time to reach undetectable SARS-CoV-2 was significantly shorter in the AP group than that in the control group. |
| T17 | 1573-1649 | Sentence | denotes | However, physicians should consider the QT interval changes before using AP. |